| Code | CSB-RA004910MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Boserolimab, targeting CD27, a member of the tumor necrosis factor receptor superfamily. CD27 is primarily expressed on T cells, B cells, and natural killer cells, where it functions as a critical costimulatory molecule regulating immune cell activation, differentiation, and survival. Upon binding to its ligand CD70, CD27 enhances T cell proliferation, cytotoxic function, and memory formation. Dysregulation of the CD27-CD70 pathway has been implicated in various malignancies and autoimmune disorders, making it an important target for immunotherapeutic interventions.
Boserolimab represents an investigational agonistic antibody designed to stimulate antitumor immunity by activating CD27 signaling, thereby enhancing T cell-mediated responses against cancer cells. This biosimilar antibody serves as a valuable research tool for investigating CD27-mediated immune mechanisms, studying costimulatory pathways in lymphocyte biology, and exploring therapeutic strategies in oncology and immunology. It enables researchers to examine immune checkpoint modulation and evaluate combination immunotherapy approaches in preclinical models.
There are currently no reviews for this product.